---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-151812"
form_type: "8-K"
ticker: "IOBTQ"
cik: "0001865494"
company_name: "IO Biotech, Inc."
filed_at: "2022-05-16T23:59:59+00:00"
generated_at: "2026-06-25T15:39:23.367285+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# IO Biotech Q1 2022 net loss $17.2M; cash $187.9M; Phase 2 trial initiated

## Summary
- Net loss of $17.2M for Q1 2022 vs $3.7M in Q1 2021; R&D expenses $10.3M (up $7.5M).
- Cash and equivalents $187.9M at March 31, 2022, down from $211.5M at Dec 31, 2021; runway to mid-2024.
- Initiated Phase 2 trial (IOB-022/KN-D38) of IO102-IO103 with pembrolizumab in first-line treatment.
- Updated Phase 1/2 data for IO102-IO103 + nivolumab in metastatic melanoma showed 73% 3-year survival probability.
- Phase 3 trial (IOB-013/KN-D18) with Merck ongoing; guidance on interim readout timing expected mid-2022.

## SEC filing metadata
- accession: 0001193125-22-151812
- form_type: 8-K
- ticker: IOBTQ
- cik: 0001865494
- company_name: IO Biotech, Inc.
- filed_at: 2022-05-16T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1865494/000119312522151812/0001193125-22-151812-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1865494/000119312522151812/d334702d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-151812
- JSON: https://secwatch.observer/filing/0001193125-22-151812.json
- Plain text: https://secwatch.observer/filing/0001193125-22-151812.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.